Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

Mol Cancer Ther (2022) 21 (1): 3–15.

DOI: https://doi.org/10.1158/1535-7163.MCT-21-0620

Published: 07 January 2022

View article

Includes: Supplementary data

Journal Articles

Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1^G2032R mutant in preclinical tumor models.

Helen Y. Zou, Lars R. Engstrom, Qiuhua Li, Melissa West Lu, Ruth Wei Tang, Hui Wang, Konstantinos Tsaparikos, Sergei Timofeevski, Justine Lam, Shinji Yamazaki, Wenyue Hu, Hovhannes Gukasyan, Nathan Lee, Ted W. Johnson, Valeria Fantin, Tod Smeal

Mol Cancer Ther (2013) 12 (11_Supplement): A277.

DOI: https://doi.org/10.1158/1535-7163.TARG-13-A277

Published: 01 November 2013

View article

Journal Articles

Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.

Mol Cancer Ther (2013) 12 (11_Supplement): C253.

DOI: https://doi.org/10.1158/1535-7163.TARG-13-C253

Published: 01 November 2013

View article

Journal Articles

Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901

Vince R. Torti, Donald Wojciechowicz, Wenyue Hu, Annette John-Baptiste, Winston Evering, Gabriel Troche, Lisa D. Marroquin, Tod Smeal, Shinji Yamazaki, Cynthia L. Palmer, Leigh Ann Burns-Naas, Shubha Bagrodia

Mol Cancer Ther (2012) 11 (10): 2274–2283.

DOI: https://doi.org/10.1158/1535-7163.MCT-11-0984

Published: 09 October 2012

View article

Includes: Supplementary data

Journal Articles

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

Helen Y. Zou, Qiuhua Li, Joseph H. Lee, Maria E. Arango, Kristina Burgess, Ming Qiu, Lars D. Engstrom, Shinji Yamazaki, Max Parker, Sergei Timofeevski, Jingrong Jean Cui, Michele McTigue, Gerrit Los, Steven L. Bender, Tod Smeal, James G. Christensen

Mol Cancer Ther (2012) 11 (4): 1036–1047.

DOI: https://doi.org/10.1158/1535-7163.MCT-11-0839

Published: 08 April 2012

View article

Includes: Supplementary data

Journal Articles

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

James G. Christensen, Helen Y. Zou, Maria E. Arango, Qiuhua Li, Joseph H. Lee, Scott R. McDonnell, Shinji Yamazaki, Gordon R. Alton, Barbara Mroczkowski, Gerrit Los

Mol Cancer Ther (2007) 6 (12): 3314–3322.

DOI: https://doi.org/10.1158/1535-7163.MCT-07-0365

Published: 18 December 2007

View article

NARROW

SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1^G2032R mutant in preclinical tumor models.

Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.

Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

Email alerts

AACR Journals

SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models.

Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.

Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1^G2032R mutant in preclinical tumor models.